October 01, 2014 12:37 AM ET

Pharmaceuticals

Company Overview of G1 Therapeutics, Inc.

Executive Profile

Seth A. Rudnick M.D.

Director, Chairman of Nominating/Corporate Governance Committee and Member of Audit Committee, POZEN Inc.
AgeTotal Calculated CompensationThis person is connected to 15 Board Members in 15 different organizations across 22 different industries.

See Board Relationships
65$110,400

Background

Dr. Seth A. Rudnick, M.D., serves as the Chairman and Scientific and Clinical Advisor of G1 Therapeutics, Inc. since January 7, 2014. Dr. Rudnick has been the Chairman of Liquidia Technologies Inc. since March 11, 2008. He serves as the Chairman of ORTHOCON Inc, Drug Innovation Ventures at Emory (DRIVE) and, Meryx. He has been a Director of Liquidia Technologies, Inc. since 2006, Square 1 Financial Inc. since November 2012, Pozen Inc. since July 2011, Abyrx, Inc. since ...

Corporate Headquarters

79 T.W. Alexander Drive
Research Triangle Park, North Carolina 27709

United States

Phone: 919-213-9835
Fax: 919-741-5830

Board Members Memberships

Former Director
Former Director
Former Chairman and Chief Executive Officer
Director
Director
Former Director
Member of Scientific Advisory Board
Director
Former Director
Director
Director
1999-2006
Former Member of the Scientific Advisory Board
2000-N/A
Former Director and Member of Compensation Committee
2000-N/A
Former Director
2001-N/A
Former Director
2006-N/A
Former Director
2006-Present
Chairman
2008-Present
Chairman of the Board
2011-Present
Director, Chairman of Nominating/Corporate Governance Committee and Member of Audit Committee
2012-Present
Director
2012-Present
Director, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee
2013-Present
Director
2014-Present
Chairman and Scientific and Clinical Advisor

Education

BA
The University of Pennsylvania
MD
University of Virginia
MD
Washington University, St. Louis
Post-Doctoral Training
Yale University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$67,750
Total Calculated Compensation$110,400
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Rajiv Kanishka Liyanaarchchie De Silva Chief Executive Officer, President and Director
Endo International plc
$4.3M
Daniel N. Swisher Jr.Chief Executive Officer, President and Director
Sunesis Pharmaceuticals, Inc.
$469.9K
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
$2.9M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
$3.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact G1 Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.